SpringWorks Therapeutics Inc - Asset Resilience Ratio
SpringWorks Therapeutics Inc (SWTX) has an Asset Resilience Ratio of 44.34% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of SpringWorks Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how SpringWorks Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SpringWorks Therapeutics Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down SpringWorks Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore SWTX long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $224.10 Million | 44.34% |
| Total Liquid Assets | $224.10 Million | 44.34% |
Asset Resilience Insights
- Very High Liquidity: SpringWorks Therapeutics Inc maintains exceptional liquid asset reserves at 44.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SpringWorks Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare SpringWorks Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for SpringWorks Therapeutics Inc (2000–2024)
The table below shows the annual Asset Resilience Ratio data for SpringWorks Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 40.57% | $238.23 Million | $587.28 Million | -1.20pp |
| 2023-12-31 | 41.77% | $303.15 Million | $725.79 Million | -41.49pp |
| 2022-12-31 | 83.26% | $524.72 Million | $630.24 Million | +23.69pp |
| 2021-12-31 | 59.57% | $269.54 Million | $452.49 Million | -3.15pp |
| 2020-12-31 | 62.72% | $361.39 Million | $576.19 Million | +61.97pp |
| 2008-12-31 | 0.76% | $282.00K | $37.28 Million | -0.03pp |
| 2007-12-31 | 0.79% | $294.00K | $37.27 Million | +0.20pp |
| 2006-12-31 | 0.59% | $209.00K | $35.50 Million | -0.43pp |
| 2005-12-31 | 1.01% | $402.00K | $39.64 Million | -0.51pp |
| 2004-12-31 | 1.53% | $686.00K | $44.95 Million | -0.25pp |
| 2003-12-31 | 1.77% | $739.00K | $41.72 Million | +1.08pp |
| 2002-12-31 | 0.69% | $531.00K | $76.58 Million | -1.50pp |
| 2001-12-31 | 2.19% | $1.60 Million | $73.16 Million | -0.11pp |
| 2000-12-31 | 2.30% | $1.85 Million | $80.46 Million | -- |
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor o… Read more